Malcolm Roberts, PhDPrincipal Scientist at Eisai Limited
Malcolm Roberts was awarded his PhD from the Department of Biochemistry, University of Cambridge in 2004. Immediately after graduation he joined the Japanese pharmaceutical company Eisai at their operational site in the UK. His expertise is neurodegenerative diseases such as Alzheimer’s and Parkinson’s and he has led a number of drug discovery projects, both small and large molecule, throughout his career in industry. Currently, Malcolm is a Principal Scientist within Eisai’s Neurology Business Group and with his team, he works closely with academic collaborators to validate novel drug targets and develop new therapeutic agents for testing in patients with neurodegenerative diseases.